Omega Diagnostics Share Discussion Threads

[rivaldo] 28/6/2016 08:36

Finncap have given a 28p price target for ODX:

[barrywhit] 27/6/2016 07:58

Very solid set of results, looking very positive going forward. Solid investment.....

[rivaldo] 27/6/2016 07:39

Indeed - a pleasing set of results, with £1.35m PBT slightly ahead of both Finncap's and Edison's forecasts. EPS would have been ahead too but for a small tax charge.

Food intolerance is surging ahead and has big growth potential globally.

Good news too from both Vistect and Allersys, and re the Indian manufacturing facility, where a malaria test is an opportunity for a third big winner.

Almost £1m net cash is more than sufficient going forward given the core profitability.

[longshanks] 27/6/2016 07:26

Good to see some positive results and - as an exporter with great niche products - they will be largely immune from the Brexit fallout.

[leedslad001] 27/6/2016 07:20

All good news today onwards and upwards this year

[rivaldo] 24/6/2016 07:17

Funnily enough, ODX will be one of those to benefit - in 2015 it specifically noted that revenues would have been higher except that the pound had strengthened against the euro, so a lower pound will be good for ODX.

As for most of the rest of UK PLC however.... :o((

[leedslad001] 24/6/2016 07:02

Hi Barry think we will ok here most on here know what's what so can't see a lot selling with all the good news just round the corner

[barrywhit] 24/6/2016 05:09

Oh dear, Tin hats on lads.......

[rivaldo] 09/6/2016 09:39

Yep - he's picked up almost another 1.3m shares since his last disclosure, so obviously very keen at these levels.

Worth remembering that Richard Sneller is a Fund Manager at Baillie Gifford, so should know his stuff more than most.

[barrywhit] 09/6/2016 09:20

So our Mr. Richard Sneller picked up the 250k @ 16p yesterday, quite a holding he has over 6% now, shows a lot of confidence in the company. Would be good to get an update on CD4 and the Allergy platform...

[gary38] 09/6/2016 09:18

Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy

[rivaldo] 22/5/2016 07:40

Thanks chaps.

Here's a good interview with the CEO which hasn't been posted and which again shows not only growing confidence re CD4, but also global ambitions for the core business:



"Sales growth of food intolerance kits fuels overseas ambitions for Omega
22 Apr 2016 / Victoria Masterson

OMEGA Diagnostics, the Clackmannanshire company that produces tests for allergies, food intolerance and infection diseases, said it was making progress on its long-awaited HIV test and that strong growth in its food intolerance business could fuel growth in China, India and North America.

“We’re getting close to a final product but we’ve still got some work to do,” said chief executive Andrew Shepherd of the portable HIV test, which is being modified to withstand very hot temperatures in sub-Saharan countries. “We’re up to 32 degrees, so it’s now just getting that test to work up to 35 degrees. It still has a great demand, because there is no CD4 test that can go down to village levels or clinics in Africa.”

CD4 cells are a type of white blood cell that fight infection and indicate the health of a person’s immune system.

In a trading update, Omega said its food Intolerance business – which sells a kit used by nutritionists and dieticians to test for 59 food intolerances and a lab test against 220 foods – had achieved its targeted double-digit revenue growth in the period, up 19 per cent to £7.1 million. However, its allergy business in Germany continued to decline as it saw a reduction in buying levels, hit by increased competition.

Results for the year to 31 March 2016 are expected to be in line with expectations, with revenues 6 per cent ahead of last year at £12.7m and adjusted pre-tax profits in the range of £1.2m to £1.3m. The company said it had identified a ‘clear organic growth strategy’ for the next three to five years.

“We’re pushing at a market that’s still developing,” said Mr Shepherd, who founded the business in 1987. “We’re not doing a lot in China at the moment but that’s a market that’s growing very quickly. We recently got our products into India through our Indian subsidiary and that’s another market with the potential for high growth. Another potential market is North America, were we’re doing very little at the moment. So there are a lot of good product markets out there and we’re very confident that growth will continue.”

House broker finnCap said the route to achieving further field trials for the HIV product was understood and closer. Omega is valued at £16m on London's Alternative Investment Market."

[bomber13] 21/5/2016 11:42

Thank you LL and Rivaldo , most interesting 4 minute Ideagen video with a few carefully prescribed shots of Visitect . Should we take this to mean a growing confidence in the product ? I guess we will find out more on 27th June .

[looby loo] 20/5/2016 13:48

Thanks Rivaldo. A bit more information about the Q-Pulse news here:

[rivaldo] 20/5/2016 06:39

Nice article about the expansion in India helped by Q-Pulse software from Ideagen (IDEA), which coincidentally I also hold!



"Ideagen : Q-Pulse is the DNA for Omega Diagnostics Group's Indian expansion
05/19/2016 | 11:03am CEST

Governance, risk and compliance software vendor, Ideagen, is helping an ambitious life science organisation expand its operations in India.

Ideagen's Q-Pulse will be the foundation for Omega Diagnostics Group 's quality and compliance management as the company launch sales and marketing operations in Mumbai and manufacturing operations in Pune.

Using Q-Pulse, Omega will customise its processes so as to tie in with the Indian GMP requirements and those of the Indian FDA, namely Schedule M. Further to the regulatory compliance benefits, Q-Pulse will allow the organisation to share learnings, best practice and core documentation as it is used extensively within its other manufacturing facilities in the UK and Germany.

Mike Gordon, Group Operations Director at Omega Diagnostics Group, said: 'Q-Pulse has been the bedrock to our quality success both in the UK and in Germany and will play a pivotal part in our success in India.

'This is a very exciting time for the Group and is quite a strategic development for the organisation. Achieving and maintaining compliance to the Schedule M in particular is crucial for us, and Q-Pulse will enable us to meet those objectives as efficiently and effectively as possible.'

Omega Diagnostics have been users of Ideagen's Q-Pulse software for several years, implementing it to centralise the Group's operations and to make it easier for management to achieve visibility across the whole organisation.

Its Indian site will be involved in the manufacturing of a range of products including rapid diagnostics tests and is looking to be fully ISO accredited by the end of 2016.

Mike added: 'The Indian expansion ties in with the overall growth and ambitions of Omega and provides us with direct access to the Indian market; reducing exporting costs and increasing profit margins.

'Similarly to our operations in the UK and Germany, Q-Pulse will provide us with a compliant document and quality management system. The system will become an essential component in us achieving ISO accreditation for our entire Indian operations in 2016.'

Paul Marshall, Ideagen's Head of Life Science, said: 'We are absolutely delighted to be playing a major part in the expansion and success of Omega Diagnostics Group.

'They are truly a customer advocate for Q-Pulse and we work hard to maintain our fruitful relationship by ensuring the continued integration of Q-Pulse within Omega's global operations."

[barrywhit] 19/5/2016 11:19

Should be fairly close to getting CE Approval for the Allergy Platform...

[p1nkfish] 06/5/2016 12:43

could be CD4 is beginning to be believed as a closer in event.

[longshanks] 06/5/2016 09:41

Showing some sparks of interest this week...Looks to me like the market is edging this up in a hunt for sellers. Background buyer?Could see 20p+ in the weeks ahead IMO.

[rivaldo] 26/4/2016 14:21

The latest forecast for ODX is 1.3p EPS for the year just ended, with 1.4p EPS for the current year.

CD4 and the allergy panel are in the price for free. IDH's turnover and m/cap are three times that of ODX, and they have a substantial installed base, so progress regarding the allergy panel is likely to have a material effect on ODX' fortunes.

I'm most interested in ODX' core business of food allergy detection. This is imo just going to grow and grow worldwide, and this alone is enough to keep me happy owning ODX shares, without any of the extra icing on the (allergy-free) cake.

[wjccghcc] 25/4/2016 08:14

That's the main problem with ODX. They've hitched their wagon to IDH but the machine take up seems unlikely to reach critical mass.

[longshanks] 25/4/2016 07:40

IDH issued a trading statement this morning. Stormy horizon for them still; the ODX allergy array may be useful for diversifying their operations.One has to ask if IDH can survive in its current form, and would a takeover of IDH be good or bad for ODX?

[rivaldo] 21/4/2016 13:53

Brief analyst comment FYI in amongst a general summary of the update:

hxxp://www.dailyrecord.co.uk/business/company-results-forecasts/omega-diagnostics-reports-full-year-7801534

"Mark Brewer, an analyst at finnCap, said: “Confirmation that the company is building inventory levels for launch of a 40 allergy panel in the near future, following positive field evaluations in Europe, is very positive.

“Visitect is still not yet ready for further field trials but the route to achieving this is understood and closer.”